Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference
Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer. Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical gaps in current k...
Gespeichert in:
Veröffentlicht in: | Clinical cancer research 2008-10, Vol.14 (20), p.6387-6395 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose: Summarize current knowledge, critical gaps in knowledge, and recommendations to advance the field of metastatic bone cancer.
Experimental Design: A multidisciplinary consensus conference was convened to review recent progress in basic and clinical research, assess critical
gaps in current knowledge, and prioritize recommendations to advance research in the next 5 years. The program addressed three
principal topics: biology of metastasis, preserving normal bone health, and optimizing bone-targeted therapies.
Results: A variety of specific recommendations were identified as important to advance research and clinical care over the next 5
years.
Conclusions : Priorities for research in bone biology include characterizing components of the stem cell niche in bone, developing oncogenic
immunocompetent animal models of bone metastasis, and investigating the unique contribution of the bone microenvironment to
tumor growth and dormancy. Priorities for research in preserving normal bone health include developing methods to measure
and characterize disseminating tumor cells, assessing outcomes from the major prevention trials currently in progress, and
improving methodologies to assess risks and benefits of treatment. Priorities for optimizing bone-targeted therapies include
advancing studies of serum proteomics and genomics to reliably identify patients who will develop bone metastases, enhancing
imaging for early detection of bone metastases and early response evaluation, and developing new tests to evaluate response
to bone-directed treatments. |
---|---|
ISSN: | 1078-0432 1557-3265 |
DOI: | 10.1158/1078-0432.CCR-08-1572 |